@endpts
endpoints.news FDA launches investigation of Novartis’ Zolgensma after cancer cases FDA weighs regulatory action on Novartis’ Zolgensma and Itvisma after reports of tumors linked to the gene therapy’s vector. 
endpoints.news Moderna ekes out a profit, its first in two years Moderna posts a $162M Q3 profit, its first in two years, on ex-US Covid sales as cancer vaccine spending climbs and norovirus plans shift. 
endpoints.news Sarepta quits enrolling for confirmatory Phase 3 trial of Elevidys Sarepta won’t resume enrollment in Elevidys’ Phase 3 ENVISION trial, betting on a new immunosuppression cohort to return the gene therapy to older boys. 
endpoints.news Seven new tumor cases reported among patients on Novartis' Zolgensma gene therapy Novartis confirms 9 tumor reports in Zolgensma patients; 2 may be linked to vector DNA integration. Over 6,000 treated since 2019 approval. 